EQS-Adhoc: M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment
|
EQS-Ad-hoc: M1 Kliniken AG / Key word(s): Investment/Miscellaneous M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment
HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are currently carefully reviewing the offer. A possible sale of the trade segment would pave the way for a clear strategic focus of M1 Kliniken AG on the fast-growing beauty business. The company will provide further information in due course. Contact: Attila Strauss, Management Board Corporate Communications E-Mail: ir@m1-kliniken.de End of Inside Information
01-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2110090 |
| End of Announcement | EQS News Service |
|
|
2110090 01-Apr-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 77,27 | 159,59 | 314,61 | 285,29 | 316,32 | 350,00 | 0,00 | |
| EBITDA1,2 | 11,33 | 8,89 | 17,82 | 15,41 | 21,01 | 31,00 | 0,00 | |
| EBITDA-Margin3 | 14,66 | 5,57 | 5,66 | 5,40 | 6,64 | 8,86 | 0,00 | |
| EBIT1,4 | 7,93 | 4,41 | 12,13 | 9,35 | 15,70 | 26,70 | 0,00 | |
| EBIT-Margin5 | 10,26 | 2,76 | 3,86 | 3,28 | 4,96 | 7,63 | 0,00 | |
| Net Profit (Loss)1 | 9,73 | 7,43 | 10,88 | 7,07 | 11,67 | 16,20 | 0,00 | |
| Net-Margin6 | 12,59 | 4,66 | 3,46 | 2,48 | 3,69 | 4,63 | 0,00 | |
| Cashflow1,7 | -5,37 | 9,54 | 15,68 | 20,77 | 7,81 | 11,00 | 0,00 | |
| Earnings per share8 | 0,56 | 0,37 | 0,45 | 0,22 | 0,54 | 0,78 | 0,93 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,50 | 0,30 | 0,40 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: wetreu NTRG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| M1 Kliniken | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0STSQ | DE000A0STSQ8 | AG | 333,55 Mio € | 14.09.2015 | Kaufen | 9F4MCHV9+6R |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 13,69 | 27,37 | 0,50 | 39,49 | 3,35 | 42,71 | 1,05 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,50 | 0,30 | 1,77% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 16.07.2025 | 05.06.2025 | 09.09.2025 | 19.11.2024 | 21.05.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +15,65% | +8,16% | +2,29% | +22,16% | +261,28% |
